Hims & Hers Health, Inc. current report, 09 July 2021

Hims & Hers Health, Inc. — Form 8-K Summary

Business context and reporting period

Hims & Hers Health, Inc., a Delaware corporation operating under the ticker HIMS, filed this Current Report on July 9, 2021, under Item 8.01 (Other Events). The filing reports a corporate action involving the company’s outstanding warrants; it does not cover a quarterly or annual reporting period.

Key financial metrics

The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating or financial metrics.

Material change versus the prior comparable period

On July 9, 2021, the company announced the redemption of all outstanding warrants to purchase shares of its Class A common stock issued under the July 22, 2019 Warrant Agreement with Continental Stock Transfer & Trust Company.

The filing text does not provide the number of warrants, redemption price, exercise price, expected proceeds, or estimated financial statement impact. It therefore does not permit a quantified comparison with a prior period.

Guidance, outlook, risks, contingencies, and unusual items

  • The warrant redemption is the principal unusual corporate action disclosed.
  • The filing does not provide management guidance, an operating outlook, or updated forecasts.
  • The filing states that the Form 8-K, press release, and Notice of Redemption are not offers to sell or solicitations to buy securities and are not offers or sales where unlawful.
  • Exhibit 99.1 is described as a press release announcing the warrant redemption, but the exhibit description identifies it as dated June 9, 2021, while the reported event date is July 9, 2021. The filing text does not clarify whether this is a typographical discrepancy.

Facts investors should verify

  • Review the Notice of Redemption for the redemption date, applicable procedures, exercise deadline, and treatment of unexercised warrants.
  • Verify the total number of warrants affected and the related exercise and redemption terms.
  • Assess whether the redemption changes potential share dilution or expected cash proceeds.
  • Confirm the date discrepancy in the description of Exhibit 99.1.